Side-by-side · Research reference

CardiogenvsCortagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED5/46 cited

BAnimal-MechanisticHUMAN-REVIEWED11/35 cited

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

Cortagen

Bioregulatory Tetrapeptide · Khavinson-School

TetrapeptideStructure

↓ LPO productsAntioxidant effectKozina 2007

AnimalEvidence level

Injectable · Animal models

01Mechanism of Action

Parameter

Cardiogen

Cortagen

Primary target

Cardiovascular cell gene expressionKhavinson 2022

Cerebral cortex tissue — molecular targets under investigation

Pathway

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007

Downstream effect

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007 Anisimov 2004

Feedback intact?

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

—

Origin

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004

Antibody development

—

02Dosage Protocols

Parameter

Cardiogen

Cortagen

Standard dose

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

—

Frequency

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

—

Evidence basis

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

Animal mechanistic studies

Route

Subcutaneous injection

Injectable (inferred from animal protocols)

Duration

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

—

Animal model dose (rat)

—

Injection protocol (dose not specified in abstracts)

Multiple injections over study period.

Avian model dose (chicken)

—

40-day injection courseKuznik 2008

Compared to epithalon in hypophysectomized and aged birds.

Human peripheral nerve study

—

Therapeutic course (protocol details not provided)

Posttraumatic recovery context — reference cited but not detailed.

04Side Effects & Safety

Parameter

Cardiogen

Cortagen

Injection site reactions

Mild erythema, induration (presumed)

—

Systemic adverse events

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

—

Immunogenicity

Unknown — no antibody development studies published

—

Long-term safety

Unknown — no extended human trials indexed in PubMed

—

Antioxidant suppression

—

Suppression of antioxidant activity noted alongside LPO reductionKozina 2007

Mechanism unclear — possible homeostatic adaptation.

Immune/hemostasis effects

—

No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008

Epithalon reversed deficits; cortagen did not.

Human safety data

—

No adverse events reported in peripheral nerve recovery context

Limited detail in available abstracts.

Absolute Contraindications

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

Cortagen

—

Relative Contraindications

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

Cortagen

—

05Administration Protocol

Parameter

Cardiogen

Cortagen

1. Reconstitution

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.

3. Timing

Variable — often evening injection. No established circadian preference.

Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.

4. Storage

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.

5. Needle

27–30G insulin syringe, 45° angle for subcutaneous administration.

—

06Stack Synergy

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis

Cortagen

— no documented stacks